A clinical imaging Study of the changes in [18F]F-AraG uptake following Radiotherapy in Non-small cell lung cancer.

Prior treatment

• Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. • Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. • Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial, starting with the screening visit through 12 weeks after the last administration of [ 18F]F-AraG.

• Histologically confirmed NSCLC, melanoma, esophageal, or breast cancer • Ongoing immunotherapy using an anti-PD-(L)1 agent • Planned to be treated with high dose (24Gy) radiotherapy per clinical indication • Be willing and able to provide written informed consent for the trial. • Have a performance status of 0-2 on the ECOG Performance Scale • Be above 18 years of age on day of signing informed consent.